A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke.

Trial Profile

A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs Fibrinolysin human (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Acronyms TALECRIS
  • Sponsors Grifols; Talecris Biotherapeutics
  • Most Recent Events

    • 21 Jun 2014 According to the European Clinical Trials Database record, status changed from recruiting to completed.
    • 09 Nov 2012 Planned End Date changed from 1 Dec 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 22 Feb 2012 'Grifols' added as trial sponsor and lead trial centre as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top